Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of miRNA-219 (micro-ribonucleic acid) compound to preparation of marker for diagnosing chronic pain and medicament for treating chronic pain

A 1.mirna-219, 2.mirna-219 technology, applied in the field of biomedicine

Inactive Publication Date: 2013-10-23
XUZHOU MEDICAL COLLEGE
View PDF1 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Purpose of the invention: The technical problem to be solved by the present invention is to overcome the deficiency of chronic pain drugs in the prior art, and develop miRNA-219 through in-depth research on miRNA, on the basis of the original use of miRNA-219, and through a large number of experimental screenings new use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of miRNA-219 (micro-ribonucleic acid) compound to preparation of marker for diagnosing chronic pain and medicament for treating chronic pain
  • Application of miRNA-219 (micro-ribonucleic acid) compound to preparation of marker for diagnosing chronic pain and medicament for treating chronic pain
  • Application of miRNA-219 (micro-ribonucleic acid) compound to preparation of marker for diagnosing chronic pain and medicament for treating chronic pain

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] 1. Preparation of chronic arthritis pain model with complete Freund's adjuvant (CFA):

[0018] SPF grade male Kunming male mice of 6 weeks were selected under isoflurane anesthesia, and 10 μl of sterile complete Freund's adjuvant (CFA; Sigma Company) was injected intradermally at two points around the left hind foot metatarsal joint. , this injection concentration can induce arthritis. 24 hours after injection, thermal and mechanical pain thresholds decreased and could be maintained for more than 3 weeks, and they were regarded as qualified mice for chronic pain modeling.

[0019] Pain behavior monitoring: Thermal hyperalgesia: Place a plexiglass box on a 3 mm thick glass plate, and use thermal radiation stimulation according to the Hargreaves method to irradiate the mouse's sole close to the glass plate. Record the time from the beginning of irradiation to the appearance of the mouse's foot lifting, and the cut-off time is 20 s. Each animal was measured 3 times, and ...

Embodiment 2

[0038] Example 2 miRNA-219 treatment of chronic pain animal experiments

[0039] 1. Modeling and grouping:

[0040] Under isoflurane anesthesia, SPF male Kunming male mice of 6 weeks were selected, and 40 μl of sterile complete Freund's adjuvant was injected intradermally at two points around the metatarsal joint of the left hind foot. This injection concentration can induce arthritis. 24 hours after injection, thermal and mechanical pain thresholds decreased and could be maintained for more than 3 weeks, and they were regarded as qualified mice for modeling; 20 mice were set up in the miRNA-219 intervention treatment group and 20 mice in the model control group.

[0041] 2. Experimental method:

[0042] miRNA-219 intervention treatment group in vivo injection intrathecal: mice were anesthetized with isoflurane, injected with miRNA-219 overexpressed chronic virus (concentration at 3.6×10 7 ~4.5×10 9 IFU / ml), 1 μl each time, injected along the middle, left and right three p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a miRNA-219 (micro-ribonucleic acid) compound to preparation of a marker for clinically diagnosing chronic pain disease and a medicament for treating chronic pain. After screening a large number of experiments, an experimental result shows that expression of miRNA-219 in blood of a chronic pain patient is regulated down, generation and formation of the chronic pain can be obviously restrained by regulating the miRNA-219 up, and quantitative analysis is further carried out on a clinical blood specimen of the chronic pain patient to show that the miRNA-219 can be used as the marker of generation of the chronic pain.

Description

technical field [0001] The invention relates to a new application of microRNA molecules, in particular to a new application of miRNA-219, and belongs to the technical field of biomedicine. Background technique [0002] MicroRNA (miRNA) is a newly discovered small 18-22 bp single-stranded RNA molecule that regulates gene expression at the post-transcriptional level. miRNA is involved in various biological processes such as cell differentiation, apoptosis and metabolism, and the abnormality of this regulatory process can cause a variety of diseases. Chronic pain is one of the most common clinical diseases that endanger human health and reduce people's quality of life, and has become a hot issue in clinical and basic scientific research. Central neurons (such as spinal cord, dorsal root and trigeminal nerve) are important parts that regulate the occurrence of chronic pain, and the plasticity changes of neurons in these parts lead to central sensitization is the key to the form...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68A61K48/00A61P29/00A61P25/04
Inventor 潘志强曹君利朱丽娇李燕强郝凌云尹翠杨曦张松唐倩
Owner XUZHOU MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com